Legal & General Group Plc Invests $4.84 Million in LeMaitre Vascular, Inc. $LMAT

Key Points

• Legal & General Group Plc acquired 50,434 shares of LeMaitre Vascular worth approximately $4.84 million, representing a 0.22% stake. Institutional investors collectively own 84.64% of the company.
• LeMaitre Vascular reported quarterly EPS of $0.74, below the $0.81 consensus estimate, while revenue rose 9.6% year over year to $70.38 million. Analysts expect full-year EPS of $2.89.
• The stock traded at $80.49, near its 12-month low, and analysts’ consensus rating was Hold with a target price of $110.60. The company also maintains a quarterly dividend of $0.25 per share, yielding about 1.2% annually.

Legal & General Group Plc acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 50,434 shares of the medical instruments supplier's stock, valued at approximately $4,840,000. Legal & General Group Plc owned 0.22% of LeMaitre Vascular at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of LMAT. Sound Income Strategies LLC boosted its stake in LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 183 shares during the period. Catalyst Capital Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the 1st quarter valued at approximately $32,000. Geneos Wealth Management Inc. lifted its holdings in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular during the 2nd quarter worth approximately $47,000. Finally, Quarry LP boosted its position in shares of LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier's stock worth $64,000 after purchasing an additional 529 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $80.49 on Friday. The stock has a market cap of $1.84 billion, a P/E ratio of 28.24, a price-to-earnings-growth ratio of 2.36 and a beta of 0.50. The company has a fifty day simple moving average of $92.18 and a 200-day simple moving average of $99.23. LeMaitre Vascular, Inc. has a 12-month low of $78.27 and a 12-month high of $118.01. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). The business had revenue of $70.38 million during the quarter, compared to analysts' expectations of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business's quarterly revenue was up 9.6% compared to the same quarter last year. During the same period last year, the company earned $0.60 EPS. Equities analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Thursday, August 20th were paid a dividend of $0.25 per share. The ex-dividend date was Thursday, August 20th. This represents a $1.00 annualized dividend and a yield of 1.2%. LeMaitre Vascular's payout ratio is presently 35.09%.

Analysts Set New Price Targets

Several equities analysts have commented on LMAT shares. Weiss Ratings downgraded shares of LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, August 14th. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 5th. Zacks Research cut LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. Citigroup restated a "market outperform" rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Finally, Wells Fargo & Company decreased their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating for the company in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $110.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source